- Open
- 224.00
- High
- 230.00
- Low
- 220.00
- Close
- 220.09
- Change
- +1.00 (0.45%)
- Volume
- 49,094
⌘K
| 9 Apr 2026 | 09:30:00 | 2025 Annual Report and Notice of AGM |
| 9 Apr 2026 | 07:00:07 | Data to be Presented at AACR Annual Meeting 2026 |
| 23 Mar 2026 | 07:00:13 | HUTCHMED Initiates Phase III Trial of HMPL-760 |
| 16 Mar 2026 | 08:30:00 | Vesting of awards under Long Term Incentive Plan |
| 11 Mar 2026 | 08:30:00 | Vesting of awards under Long Term Incentive Plan |
HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.
| 9 Apr 2026 | 09:30:00 | 2025 Annual Report and Notice of AGM |
| 9 Apr 2026 | 07:00:07 | Data to be Presented at AACR Annual Meeting 2026 |
| 23 Mar 2026 | 07:00:13 | HUTCHMED Initiates Phase III Trial of HMPL-760 |
| 16 Mar 2026 | 08:30:00 | Vesting of awards under Long Term Incentive Plan |
| 11 Mar 2026 | 08:30:00 | Vesting of awards under Long Term Incentive Plan |
HUTCHMED is a biopharmaceutical company that focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases on a global scale. They are dedicated to innovation and commercialization in the field of biopharmaceuticals.